Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAB-185 in Ambulatory COVID-19
NCT04469179Phase 1Unknown
- Sponsor
- SAB BIO
- Start
- Aug 2020
- Primary completion
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SAB-185 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by SAB BIO. Primary endpoints: Number of Participants Having Adverse Events at 29 Days and Number of Participants Having Transfusion-Related Adverse Events at 29 Days. Status: unknown.
02
Drugs
SAB-185
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04469179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04469179.